Testing a New Method for Diagnosing PSP and CBS
Author Information
Author(s): Vaughan David P., Fumi Riona, Theilmann Jensen Marte, Hodgson Megan, Georgiades Tatiana, Wu Lesley, Lux Danielle, Obrocki Ruth, Lamoureux Jennifer, Ansorge Olaf, Allinson Kieren, Warner Thomas, Jaunmuktane Zane, Misbahuddin Anjum, Leigh P. Nigel, Ghosh Boyd, Bhatia Kailash, Church Alistair, Kobylecki Christopher, Hu Michele T.M., Rowe James B., Blauwendraat Cornelis, Morris Huw R., Jabbari Edwin
Primary Institution: UCL Queen Square Institute of Neurology
Hypothesis
Can the α-synuclein seed amplification assay (SAA) effectively identify cases of progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS)?
Conclusion
The study found that α-synuclein seeds can be detected in cerebrospinal fluid from patients with PSP and CBS, which may influence clinical outcomes.
Supporting Evidence
- 10.2% of PSP cases tested positive for α-synuclein SAA.
- 29.7% of CBS cases tested positive for α-synuclein SAA.
- Older PSP patients showed a trend towards more severe symptoms.
- PSP cases with PD-type positivity had a shorter disease duration.
- High rates of primary 4-repeat tau pathology were confirmed postmortem.
Takeaway
Researchers tested a new way to find a specific protein in the fluid around the brain to help diagnose certain brain diseases, and it worked for some patients.
Methodology
The study analyzed cerebrospinal fluid samples from 96 patients diagnosed with PSP and CBS using the α-synuclein SAA.
Potential Biases
Potential interrater variability in clinical measures.
Limitations
The study had low power to detect small differences and did not include healthy control subjects.
Participant Demographics
Participants included 59 with PSP and 37 with CBS, with a mean age of 69 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website